Generics in Europe

Datamonitor, September 2010, Pages: 43

The Generics in Europe industry profile is an essential resource for top-level data and analysis covering the Generics industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.

Scope

- Contains an executive summary and data on value, volume and/or segmentation

- Provides textual analysis of Generics in Europe’s recent performance and future prospects

- Incorporates in-depth five forces competitive environment analysis and scorecards

- Includes a five-year forecast of Generics in Europe

- The leading companies are profiled with supporting key financial metrics

- Supported by the key macroeconomic and demographic data affecting the market

Highlights

- Detailed information is included on market size, measured by value and/or volume

- Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape

Why you should buy this report

- Spot future trends and developments

- Inform your business decisions

- Add weight to presentations and marketing materials

- Save time carrying out entry-level research

Market Definition

For the purposes of this Profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices. Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume. All currency conversions were calculated at constant average annual 2009 exchange rates.

For the purposes of this report, Europe consists of Western Europe and Eastern Europe.

Western Europe comprises Belgium, Denmark, France, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom.

Eastern Europe comprises the Czech Republic, Hungary, Poland, Romania, Russia, and Ukraine.

EXECUTIVE SUMMARY
MARKET OVERVIEW
Market definition
Research highlights
Market analysis
MARKET VALUE
MARKET VOLUME
MARKET SEGMENTATION II
FIVE FORCES ANALYSIS
Summary
Buyer power
Supplier power
New entrants
Substitutes
Rivalry
LEADING COMPANIES
Bayer AG
Novartis AG
Sanofi-Aventis SA
STADA Arzneimittel AG
MARKET FORECASTS
Market value forecast
Market volume forecast
APPENDIX
Methodology
Industry associations
Related Datamonitor research
Disclaimer
ABOUT OUR
Premium Reports
Summary Reports
Datamonitor consulting

LIST OF TABLES
Table 1: Europe generics market value: $ billion, 2005-09
Table 2: Europe generics market volume: volume penetration, 2005-09
Table 3: Europe generics market segmentation II: % share, by value, 2009
Table 4: Bayer AG: key facts
Table 5: Bayer AG: key financials ($)
Table 6: Bayer AG: key financials (€)
Table 7: Bayer AG: key financial ratios
Table 8: Novartis AG: key facts
Table 9: Novartis AG: key financials ($)
Table 10: Novartis AG: key financial ratios
Table 11: Sanofi-Aventis SA: key facts
Table 12: Sanofi-Aventis SA: key financials ($)
Table 13: Sanofi-Aventis SA: key financials (€)
Table 14: Sanofi-Aventis SA: key financial ratios
Table 15: STADA Arzneimittel AG: key facts
Table 16: STADA Arzneimittel AG: key financials ($)
Table 17: STADA Arzneimittel AG: key financials (€)
Table 18: STADA Arzneimittel AG: key financial ratios
Table 19: Europe generics market value forecast: $ billion, 2009-14
Table 20: Europe generics market volume forecast: volume penetration, 2009-14

LIST OF FIGURES
Figure 1: Europe generics market value: $ billion, 2005-09
Figure 2: Europe generics market volume: volume penetration, 2005-09
Figure 3: Europe generics market segmentation II: % share, by value, 2009
Figure 4: Forces driving competition in the generics market in Europe, 2009
Figure 5: Drivers of buyer power in the generics market in Europe, 2009
Figure 6: Drivers of supplier power in the generics market in Europe, 2009
Figure 7: Factors influencing the likelihood of new entrants in the generics market in Europe, 2009
Figure 8: Factors influencing the threat of substitutes in the generics market in Europe, 2009
Figure 9: Drivers of degree of rivalry in the generics market in Europe, 2009
Figure 10: Bayer AG: revenues & profitability
Figure 11: Bayer AG: assets & liabilities
Figure 12: Novartis AG: revenues & profitability
Figure 13: Novartis AG: assets & liabilities
Figure 14: Sanofi-Aventis SA: revenues & profitability
Figure 15: Sanofi-Aventis SA: assets & liabilities
Figure 16: STADA Arzneimittel AG: revenues & profitability
Figure 17: STADA Arzneimittel AG: assets & liabilities
Figure 18: Europe generics market value forecast: $ billion, 2009-14
Figure 19: Europe generics market volume forecast: volume penetration, 2009-14

- Ratiopharm Inc.
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries

Customers who bought this item also bought

• Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs
• Global Generics Market Capsule - 2012
• Generics in Europe
• The Pricing and Reimbursement Environment for Neurology Drugs
• The Pharmaceutical Market: Germany
• Generics in Germany
• Global Biosimilars Market - Products, Applications and Regulations
• Will Big Pharma Find Success in Generics?
• Opportunities in Emerging Markets - Central and Eastern Europe, Russia, and Ukraine
• Biosimilars - Global Strategic Business Report